Cetero Research has expanded its San Antonio operations with a new purpose-built, 100-bed facility designed to run clinical pharmacology studies in healthy, diabetic and obese participants. The new facility consolidates its operations into a single four-story building.

“The site has conducted clinical studies for more than 25 years. We are excited that this new building further expands our capabilities and capacity for clinical research. One notable expansion is increased capacity to perform euglycemic and insulin-clamp studies,” said Dr. Sherwyn Schwartz, chief executive officer of Cetero’s San Antonio facility. “These specialized studies are ideal for establishing proof-of-concept for novel compounds, or even comparing compounds to show superiority or equivalence.”

“Our staff is very excited about working under one roof in the new facility. The building was designed to house healthy and patient populations participating in first-in-human and proof-of-concept studies, as well as very complex euglycemic and insulin-clamp studies,” said Dr. Robert Earl, president of Cetero’s San Antonio facility. “San Antonio’s highly-respected principal investigators, nurses and study managers have many years of experience running Phase I to Phase IV studies for biotechnology, device and pharmaceutical companies.”

The facility is located on the Christus Santa Rosa Medical Campus and provides access to Type I and Type II diabetics and obese patients, as well as patients with hypogonadism, neuropathy, osteoporosis and erectile dysfunction.